Trial Profile
Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Relacorilant (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Corcept Therapeutics
- 09 Dec 2022 The study protocol amended as primary end-point changed from maximum tolerated dose with time frame 24 months to dose limiting toxicity with time frame up to 28 days.
- 18 May 2022 Results assessing whether combining relacorilant with taxanes can enhance anti tumor activity, published in the Clinical Cancer Research
- 17 Nov 2020 Status changed from active, no longer recruiting to completed.